JPRN-jRCT2061200026已完成3 期
The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity. Upon completion of the initial 52-week treatment period, patients will be offered an additional Open Label Extension period of at least 1 year, with benralizumab treatment and ongoing study assessments. - MESSINA
Hibi Kazushige0 个研究点目标入组 170 人开始时间: 2020年11月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Patients 12 to 65 years of age, inclusive, at the time of signing the informed consent or assent (if applicable) form.
- •- Documented previous diagnosis of EoE by endoscopy.
- •- Must be symptomatic at Visit 1 (screening) and Visit 2 (randomization)
- •1. A patient reported average of at least 2 days per week with an episode of dysphagia over the 4 weeks prior to the Visit 1 AND
- •2. An average of at least 2 days per week with an episode of dysphagia (Daily DSQ 2 or more) between Visit 1 and Visit 2, and at least 2 days per week with an episode of dysphagia (Daily DSQ 2 or more) in each of the 2 weeks immediately prior to randomization
- •- May be on background medications for EoE and related treatments during the study as long as the background medications have been stable for at least 4 weeks (8 weeks for PPI) prior to the screening. and there is agreement not to change type of background medication or dosage during the run-in period and for the first 52 weeks of the study unless a change is medically indicated.
- •- Negative serum pregnancy test for female patients of childbearing potential at Visit1.
- •- Women of childbearing potential must agree to use a highly effective form of birth control (confirmed by the Investigator) from randomization throughout the study duration and within 12 weeks after last dose if IP
排除标准
- •- Other GI disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, or celiac disease.
- •- Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation during the run-in period.
- •- Esophageal dilation performed within 8 weeks prior to screening.
- •- Use of a feeding tube, or not eating solid food daily during the run-in period.
- •- Hypereosinophilic syndrome, defined by multiple organ involvement and persistent blood eosinophil count greater than1500 eos/ micro little.
- •- EGPA vasculitis.
- •- Eosinophilic gastritis, gastroenteritis, enteritis, or colitis documented by biopsy.
- •- Current malignancy, or history of malignancy with some specific exceptions.
- •- History of anaphylaxis to any biologic therapy or vaccine.
- •- Current active liver disease:
- •_Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen [HBsAg] or hepatitis C antibody), or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria.
- •_Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level equal or greater than 3 times the upper limit of normal (ULN), confirmed by repeated testing during the run-in period.
- •- Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent or assent (if applicable) is obtained that has not been treated with or has failed to respond to standard of care therapy.
- •- History of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
- •- Concomitant use of immunosuppressive medication.
- •- Initiation or change of a food-elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to start of the run-in period.
- •- Currently pregnant, breastfeeding, or lactating women.
研究者
相似试验
已完成
3 期
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)Eosinophilic EsophagitisNCT03633617Regeneron Pharmaceuticals321
进行中（未招募）
不适用
Prelude A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - NDEUCTR2005-004630-41-ITELI LILLY459
进行中（未招募）
1 期
A three-stage clinical trial to assess the safety, the effect and the pharmacokinetics of the drug niclosamide in the treatment of patients with the condition ulcerative proctitis or ulcerative procto-sigmoiditisEUCTR2017-000319-18-DEFirst Wave BioPharma, Inc.105
进行中（未招募）
1 期
Phase I/IIa, three-stage study to investigate the safety, the efficacy and the pharmacokinetics of niclosamide enemas in subjects with active ulcerative proctitis or ulcerative procto-sigmoiditislcerative Proctitis (UP) or Ulcerative Procto-Sigmoiditis (UPS)MedDRA version: 20.0Level: PTClassification code 10036783Term: Proctitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: LLTClassification code 10036789Term: ProctosigmoiditisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10045362Term: Ulcerative (chronic) proctosigmoiditisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-000319-18-ATFirst Wave BioPharma, Inc.105
招募中
3 期
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast CancerBreast Cancer, Early Breast CancerJPRN-jRCT2031230096Hibi Kazushige430